Abstracts Archive - Page 2001 of 2616 - ACR Meeting Abstracts

Abstract Number: 1812 • 2015 ACR/ARHP Annual Meeting
The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus
Tomonori Ishii¹, Yoshiya Tanaka², Atsushi Kawakami³, Kazuyoshi Saito², Kunihiro Ichinose⁴, Yuko Shirota⁵, Hiroshi Fujii⁵, Yoko Fujita⁶, Yukiko Kamogawa⁵, Tomoaki Machiyama⁵, Kanae Akita⁵ and Hideo Harigae⁵, ¹Department of Clinical Trial Implementation, Tohoku University Hospital, Clinical Research, Innovation and Education Center, Sendai, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁶Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease characterized by production and deposition of anti-dsDNA antibody. In recent years, treatment methods targeting antibody-producing B cell…
Abstract Number: 1813 • 2015 ACR/ARHP Annual Meeting
Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production
Jie An¹, Joshua Woodward², Mark Minie³, YuFeng Peng⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, Department of Medicine & Immunology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Bioengineering, University of Washington, Seattle, WA, ⁴Rheumatology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Department of Medicine & Immunology, University of Washington, Seattle, WA
Background/Purpose: Anti-malarial drugs (AMD) such as Hydroxychloroquine (HCQ) and Quinacrine (QC) are effective in the treatment of skin rash and arthritis in systemic lupus erythematosus…
Abstract Number: 1814 • 2015 ACR/ARHP Annual Meeting
Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients
Jin Young Moon, Hyun Mi Kwon, Eun Young Ahn, Jin Kyun Park, Yeong Wook Song and Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Treatment of lupus nephritis requires aggressive immunosuppressive drugs which includes high dose glucocorticoids. Immunosuppressive treatment is a risk factor for opportunistic infections such as…
Abstract Number: 1815 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence
Laura Durcan¹, William Clarke², Laurence S Magder³ and Michelle Petri¹, ¹Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ²Department of Pathology, Clinical Chemistry., Johns Hopkins University Hospital, Baltimore, MD, ³Epidemiology and Preventive Medicine, University of MD, Baltimore, MD
Background/Purpose: Hydroxychloroquine is at the cornerstone of systemic lupus erythematosus (SLE) management. It is used for both its effect on disease activity and long-term benefits.…
Abstract Number: 1816 • 2015 ACR/ARHP Annual Meeting
Long-Term Outcome of Tacrolimus Therapy As a Maintenance Strategy in Patients with Lupus Nephritis
Yun Jung Choi¹, Won-Seok Lee², Myong-Joo Hong³, Chang-Hoon Lee⁴, Myeung Su Lee⁵, Young Sun Suh⁶, Sang-Il Lee⁷ and Wan-Hee Yoo⁸, ¹Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, JeonJu, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, jeonju, South Korea, ³Internal Medicine, Presbyterian Medical center, Jeonju, South Korea, ⁴Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ⁵Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, ⁸Division of Rhuematology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, Jeonju, South Korea
Background/Purpose: Lupus nephritis(LN) is one of the significant cause of mortality in patients with systemic lupus erythematosus. Tacrolimus, a calcineurin inhibitor widely used in prevention…
Abstract Number: 1817 • 2015 ACR/ARHP Annual Meeting
Myocardial Tissue Characterization with Native Myocardial T1 Mapping in SLE Patients with Chest Pain
Jaime Shaw¹, Mariko L. Ishimori², Vaneet K. Sandhu², Behzad Sharif³, Louise Thomson⁴, Debiao Li¹, Jay Schapira⁴, Daniel Wallace³, Noel Bairey Merz⁴, Michael Weisman³ and Daniel Berman⁴, ¹Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: SLE patients often exhibit signs and symptoms of cardiac ischemia with an overall increased prevalence of coronary artery disease (CAD), microvascular dysfunction and myocarditis…
Abstract Number: 1818 • 2015 ACR/ARHP Annual Meeting
Cyclophosphamide and Cumulative Steroid Dose Associated with Higher Risk of Infections in Patients with Lupus Nephritis
Shubhasree Dutta Choudhury¹, Ann Biehl², Maryam Ghaderi-yeganeh³, Zerai Manna⁴ and Sarfaraz Hasni⁴, ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases2, National Institutes of Health, Bethesda, MD, ²Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, ³National Institutes of Health Clinical Center Department of Pharmacy, National Institutes of Health, Bethesa, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Immune dysregulation associated with SLE leads to a substantially high background risk of infection. This risk of infection further increases with the use of…
Abstract Number: 1819 • 2015 ACR/ARHP Annual Meeting
Comparison of Electrocardiographic ST-T Changes and QTc Duration in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Laura Geraldino-Pardilla¹, Yevgeniya Gartshteyn², Jon T. Giles³, Thania Perez⁴, Anca D. Askanase⁵ and Joan M. Bathon⁶, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University, College of Physicians & Surgeons, New York, NY, ³Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Columbia University, College of Physicians & Surgeons, New York, NY, ⁵Department of Medicine Rhemuatology, Colombia University, New York, NY, ⁶Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of death in systemic lupus erythematosus (SLE) and in rheumatoid arthritis (RA). Longer corrected QT segments (QTc)…
Abstract Number: 1820 • 2015 ACR/ARHP Annual Meeting
Prevalence and Risk-Factors for Asymptomatic Coronary-Artery Calcifications in Young Patients with Systemic Lupus Erythematosus
Juanita Romero-Diaz¹, Rocio Moran-Contla², Eric Kimura-Hayama³, Sergio Criales-Vera³, Carlos Núñez-Álvarez², Roberto Ivan Acosta-Hernandez⁴, Mario César Ocampo-Torres⁵ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ²Instituto Nacional de Cs Medicas y Nutricion Salvador Zubiran, Mexico city, Mexico, ³Radiology Department, Instituto Nacional de Cardiologia, Mexico City, Mexico, ⁴Society for Worldwide Med Exchange, North Bay Village, FL, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Premature atherosclerosis is a major cause of morbidity and mortality in females with systemic lupus erythematosus (SLE), but little is known about the frequency,…
Abstract Number: 1821 • 2015 ACR/ARHP Annual Meeting
Leptin, Adiponectin, and Resistin As Serum Markers of Fatigue in Systemic Lupus Erythematosus: A Pilot Study
Mary Mahieu¹, Grace Ahn², Joan S. Chmiel³, Dorothy D. Dunlop⁴, Irene Helenowski³, Pamela Semanik⁵, Jing Song⁴, Rowland W. Chang³ and Rosalind Ramsey-Goldman⁶, ¹Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Rheumatology, Falls Medical Specialists, Baltimore, MD, ³Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Institute for Healthcare Studies, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Nursing, Rush University College of Nursing, Chicago, IL, ⁶Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Fatigue, a common symptom in systemic lupus erythematosus (SLE) patients, is ameliorated by physical activity. Adiposity and adipokines may be associated with patient-reported fatigue.…
Abstract Number: 1822 • 2015 ACR/ARHP Annual Meeting
Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus
Mukul Minocha¹, Shekman Wong², Jiewei Zeng², Peng Lu³, Jeroen Medema² and Ahmed Othman⁴, ¹Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., Worcester, MA, ⁴AbbVie, North Chicago, IL
Background/Purpose: Selective Inhibition of Bcl-2 pathway may offer clinical efficacy in Systemic Lupus Erythromatosus (SLE) by restoring apoptosis in autoreactive cells, which may lead to…
Abstract Number: 1823 • 2015 ACR/ARHP Annual Meeting
Visceral Adiposity in Premenopausal Lupus Patients: Correlation with Systemic Inflammation
Luciana Seguro¹, Valéria Caparbo², Eloisa Bonfá¹ and Rosa M R Pereira³, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: SLE is associated with high prevalence of metabolic syndrome and obesity, which can be related to the high risk of cardiovascular events in this…
Abstract Number: 1824 • 2015 ACR/ARHP Annual Meeting
Tripterygium Wilfordii for the Treatment of Systemic Lupus Systematosus: Meta-Analysis of Randomized Controlled Trials
Yixia Ye¹, Bo Chen², Robert A. Kalish³ and Chenchen Wang⁴, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Orthopaedics and Traumatology, Shuguang Hospital affiliated to Shanghai University of T.C.M., Shanghai, China, ³Medicine, Tufts Medical Center, Boston, MA, ⁴Rheumatology, Tufts Medical Center, Bosotn, MA
Background/Purpose: Tripterygium Wilfordii (TPW), a Chinese herbal medication, has been widely used in China for various chronic inflammatory and autoimmune diseases, including systemic lupus erythematosus…
Abstract Number: 1825 • 2015 ACR/ARHP Annual Meeting
Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification
Indu Poornima¹, Kelly J. Shields², Susan Manzi³, Rosalind Ramsey-Goldman⁴, Carrie Richardson⁵, Lewis Kuller⁶, George Kondos⁷, James Carr⁵, Craig Langman⁵, Heather Price⁵, Daniel Edmundowicz⁸ and Rachel Mackey⁹, ¹Division of Cardiology, Allegheny Health Network, Pittsburgh, PA, ²Rheumatology, Allegheny Singer Research Institute, Pittsburgh, PA, ³Rheumatology, Allegheny Health Network, Pittsburgh, PA, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Evanston, IL, ⁶Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁷University of Illinois in Chicago, Chicago, IL, ⁸Cardiology, Temple University School of Medicine, Philadelphia, PA, ⁹Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In the general population, we and others have reported that higher osteoprotegerin (OPG), a protein involved in bone remodeling, is associated with higher levels…
Abstract Number: 1826 • 2015 ACR/ARHP Annual Meeting
Small LDL-P Increases with Increased Disease Activity in SLE
Laura Durcan¹, Deborah Winegar², Margery Connelly², James Otvos², Laurence S Magder³ and Michelle Petri¹, ¹Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ²LabCorp, Raleigh, NC, ³Epidemiology and Preventive Medicine, University of MD, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) associates with accelerated atherosclerotic cardiovascular (CV) disease which is not fully explained by traditional CV risk factors. Disease activity, prednisone…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].